NxStage Medical, Inc. (NXTM) President Sells $29,260.00 in Stock
NxStage Medical, Inc. (NASDAQ:NXTM) President Joseph E. Turk, Jr. sold 1,000 shares of the stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $29.26, for a total value of $29,260.00. Following the completion of the sale, the president now directly owns 74,903 shares of the company’s stock, valued at $2,191,661.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
NxStage Medical, Inc. (NASDAQ:NXTM) traded down 0.03% during trading on Thursday, hitting $29.28. The stock had a trading volume of 3,861,757 shares. NxStage Medical, Inc. has a 1-year low of $20.45 and a 1-year high of $30.80. The company’s market capitalization is $1.93 billion. The stock’s 50-day moving average price is $24.57 and its 200-day moving average price is $25.80.
NxStage Medical (NASDAQ:NXTM) last announced its earnings results on Monday, August 7th. The medical device company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03). The business had revenue of $92.20 million during the quarter, compared to analyst estimates of $96.47 million. NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.46%. The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.03) EPS. Analysts expect that NxStage Medical, Inc. will post ($0.03) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “NxStage Medical, Inc. (NXTM) President Sells $29,260.00 in Stock” was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/08/10/nxstage-medical-inc-nxtm-president-sells-29260-00-in-stock.html.
Several brokerages have recently commented on NXTM. Jefferies Group LLC downgraded NxStage Medical from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $33.00 to $30.00 in a research note on Tuesday. William Blair downgraded NxStage Medical from an “outperform” rating to a “market perform” rating in a research note on Monday. Northland Securities reissued a “hold” rating and issued a $30.00 price objective on shares of NxStage Medical in a research note on Monday. Zacks Investment Research raised NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 target price for the company in a report on Thursday. Finally, Canaccord Genuity lowered NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 target price for the company. in a report on Monday. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the stock. NxStage Medical presently has a consensus rating of “Hold” and an average target price of $30.29.
A number of large investors have recently made changes to their positions in NXTM. SG Americas Securities LLC bought a new stake in shares of NxStage Medical during the first quarter worth $140,000. Ameritas Investment Partners Inc. bought a new stake in shares of NxStage Medical during the first quarter worth $148,000. Quantitative Systematic Strategies LLC bought a new stake in shares of NxStage Medical during the second quarter worth $203,000. Menta Capital LLC bought a new stake in shares of NxStage Medical during the first quarter worth $212,000. Finally, Jane Street Group LLC bought a new stake in shares of NxStage Medical during the first quarter worth $213,000. Institutional investors and hedge funds own 91.11% of the company’s stock.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.